| Literature DB >> 25191589 |
Yoshitaka Hirose1, Yoshihiro Yamamoto1, Yasunobu Yoshikai2, Shinji Murosaki1.
Abstract
The immunomodulatory effects of live or non-viable lactic acid bacteria have been extensively investigated. We reported that oral intake of heat-killed Lactobacillus plantarum L-137 (HK L-137) augmented innate and acquired immunity in mice and human subjects. To examine the effects of HK L-137 intake on upper respiratory tract infection (URTI) symptoms and immune functions in human subjects, a randomised, double-blind, placebo-controlled, parallel study was conducted in subjects with high psychological stress levels. A total of seventy-eight healthy subjects (thirty-three men and forty-five women; mean age 50·6 years) with scores of >41 on eighteen-item subscales of psychological distress in the Brief Job Stress Questionnaire were randomly assigned to receive a tablet containing HK L-137 (10 mg) or a placebo tablet daily for 12 weeks. The URTI symptoms were rated once daily on the validated twenty-one-item Wisconsin Upper Respiratory Symptom Survey-21. Immune functions, such as concanavalin A-induced proliferation and percentages of interferon (IFN)-γ- and IL-4-producing CD4 T cells of peripheral blood mononuclear cells (PBMC), and serum IFN-β concentrations were measured every 4 weeks. URTI incidence was significantly lower in the HK L-137 group than in the control group. URTI incidence, duration and severity, and duration of medication showed significant negative correlations with duration of HK L-137 intake. The percentage change from baseline of concanavalin A-induced proliferation of PBMC was significantly greater in the HK L-137 group than in the control group. These findings suggest that daily HK L-137 intake can decrease URTI incidence in healthy subjects, possibly through augmentation of immune functions.Entities:
Keywords: Con A, concanavalin A; HK L-137, heat-killed Lactobacillus plantarum L-137; IFN, interferon; Immune function; Lactobacillus plantarum; PBMC, peripheral blood mononuclear cells; Stress; Th, T helper; URTI, upper respiratory tract infection; Upper respiratory tract infections; WURSS, Wisconsin Upper Respiratory Symptom Survey; WURSS-21, short-form Wisconsin Upper Respiratory Symptom Survey; WURSS-44, long-form Wisconsin Upper Respiratory Symptom Survey; Wisconsin Upper Respiratory Symptom Survey
Year: 2013 PMID: 25191589 PMCID: PMC4153334 DOI: 10.1017/jns.2013.35
Source DB: PubMed Journal: J Nutr Sci ISSN: 2048-6790
Fig. 1.Subject flowchart summarised according to Consolidated Standards of Reporting Trials (CONSORT) that shows the number of subjects randomly assigned, lost to follow-up and analysed by treatment arm. HK L-137, heat-killed Lactobacillus plantarum L-137; URTI, upper respiratory tract infection.
Baseline psychological stress scores and immune characteristics of the subjects enrolled in the present study
(Mean values and standard deviations)
| Control | HK L-137 | All subjects | ||||
|---|---|---|---|---|---|---|
| Mean |
| Mean |
| Mean |
| |
| Subjects ( | 39 | 39 | 78 | |||
| Sex ( | ||||||
| Male | 14 | 19 | 33 | |||
| Female | 25 | 20 | 45 | |||
| Age (years) | 51·5 | 7·2 | 49·6 | 6·8 | 50·6 | 7·0 |
| Immune function | ||||||
| Unstimulated proliferation (×103 cpm) | 0·23 | 0·12 | 0·22 | 0·09 | 0·23 | 0·11 |
| Con A-induced proliferation (×103 cpm) | 29·3 | 6·9 | 28·4 | 9·0 | 28·8 | 8·0 |
| IFN-γ-producing cells (Th1 cells) (% CD4+ cells) | 22·6 | 8·1 | 23·4 | 7·0 | 23·0 | 7·5 |
| IL-4-producing cells (Th2 cells) (% CD4+ cells) | 2·9 | 1·2 | 2·6 | 1·0 | 2·7 | 1·1 |
| Th1:Th2 ratio | 9·2 | 5·2 | 10·4 | 5·2 | 9·8 | 5·2 |
| Serum IFN-β (IU/ml)* | 11·3 | 35·1 | 17·4 | 49·3 | 14·3 | 42·6 |
| Total psychological stress scores* | 59·6 | 4·4 | 58·5 | 4·0 | 59·0 | 4·2 |
HK L-137, heat-killed Lactobacillus plantarum L-137; Con A, concanavalin A; cpm, counts per min; IFN, interferon; Th1, type 1 T helper; Th2, type 2 T helper.
* Compared between the two groups by the Mann–Whitney U test.
Scores for incidence, duration, mental severity and physical severity of upper respiratory tract infection (URTI), and duration of medication in subjects with daily intake of a tablet containing 10 mg of heat-killed Lactobacillus plantaru m L-137 (HK L-137) or a control tablet*
| Intervention period | Friedman test: | Spearman's rank-correlation coefficient‡ | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| End point | 1 week | 2 weeks | 3 weeks | 4 weeks | 5 weeks | 6 weeks | 7 weeks | 8 weeks | 9 weeks | 10 weeks | 11 weeks | 12 weeks | Intervention | Time point | Correlation coefficient |
| |
| Incidence (number of cases) | Control | 7 | 6 | 5 | 3 | 3 | 4 | 3 | 4 | 2 | 3 | 5 | 2 | 0·011 | 0·075 | −0·619 | 0·032 |
| HK L-137 | 6 | 5 | 4 | 6 | 0 | 2 | 3 | 3 | 0 | 1 | 3 | 2 | −0·627 | 0·029 | |||
| Duration (d) | Control | 20 | 16 | 8 | 24 | 9 | 10 | 6 | 14 | 10 | 7 | 23 | 12 | 1·000 | 0·172 | −0·165 | 0·609 |
| HK L-137 | 19 | 23 | 24 | 31 | 15 | 8 | 12 | 15 | 0 | 4 | 11 | 9 | −0·753 | 0·005 | |||
| Mental severity | Control | 37 | 28 | 10 | 30 | 9 | 22 | 11 | 26 | 22 | 11 | 40 | 17 | 0·564 | 0·445 | −0·098 | 0·761 |
| HK L-137 | 31 | 73 | 58 | 49 | 36 | 13 | 22 | 38 | 0 | 14 | 13 | 10 | −0·776 | 0·005 | |||
| Physical severity | Control | 280 | 271 | 56 | 205 | 24 | 296 | 54 | 171 | 115 | 65 | 249 | 137 | 0·564 | 0·443 | −0·224 | 0·484 |
| HK L-137 | 209 | 953 | 883 | 492 | 202 | 137 | 226 | 273 | 0 | 169 | 104 | 42 | −0·734 | 0·007 | |||
| Duration of medication (d) | Control | 10 | 12 | 2 | 3 | 1 | 6 | 1 | 4 | 6 | 3 | 3 | 7 | 0·132 | 0·548 | −0·117 | 0·718 |
| HK L-137 | 7 | 6 | 8 | 7 | 6 | 0 | 0 | 2 | 0 | 3 | 1 | 0 | −0·722 | 0·008 | |||
Control group, n 39; HK L-137 group, n 39.
† Significant differences estimated between the two groups at the time points.
‡ Correlations between the symptoms of URTI, and duration of medication and duration of control tablet or HK L-137 intake.
Percentage changes in immune characteristics from baseline in subjects with daily intake of a tablet containing 10 mg of heat-killed Lactobacillus plantarum L-137 (HK L-137) or a control tablet without upper respiratory tract infection (URTI) symptoms throughout the intervention period*
(Mean values and standard deviations)
| Change from baseline (%) | ANOVA: | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks | 8 weeks | 12 weeks | Intervention | Time point | Interaction‡ | |||||
| Unstimulated proliferation ( × 103 cpm) | Control | 22·5 | 73·7 | 8·1 | 37·9 | –0·5 | 38·2 | 0·425 | 0·016 | 0·566 |
| HK L-137 | 29·9 | 90·1 | –5·3 | 34·9 | –21·4 | 37·1 | ||||
| Con A-induced proliferation ( × 103 cpm) | Control | −22·4 | 18·1 | –13·1 | 22·0 | −7·8 | 28·5 | 0·048 | 0·535 | 0·679 |
| HK L-137 | −3·8 | 28·9 | –3·9 | 37·4 | –0·9 | 32·4 | ||||
| IFN-γ-producing cells (Th1 cells) (%CD4+ cells) | Control | 9·1 | 18·1 | 1·6 | 12·6 | 8·5 | 17·6 | 0·455 | 0·360 | 0·883 |
| HK L-137 | 5·8 | 20·1 | 1·3 | 14·0 | 4·1 | 21·3 | ||||
| IL-4-producing cells (Th2 cells) (%CD4+ cells) | Control | 18·2 | 41·6 | 13·5 | 44·3 | −4·1 | 39·9 | 0·870 | 0·010 | 0·879 |
| HK L-137 | 20·1 | 45·0 | 14·7 | 40·9 | −10·9 | 21·5 | ||||
| Th1:Th2 ratio | Control | 6·6 | 48·0 | 4·2 | 49·1 | 35·3 | 70·7 | 0·449 | 0·048 | 0·938 |
| HK L-137 | 1·3 | 51·6 | –0·4 | 39·6 | 22·9 | 38·1 | ||||
| Serum IFN-β | Control | 0·2 | 6·8 | −0·5 | 1·3 | 0·9 | 4·5 | – | – | – |
| HK L-137 | −5·4 | 14·6 | −6·7 | 31·3 | −6·1 | 29·5 | ||||
cpm, Counts per min; Con A, concanavalin A; IFN, interferon; Th1, type 1 T helper; Th2, type 2 T helper.
* Control group: n 15; HK-LP group: n 20.
† Significant differences between the two groups at the time points were evaluated by two-way ANOVA. Serum IFN-β concentrations were compared between the two groups at each time point by the Mann–Whitney U test.
‡ Interaction between intervention and time point.